112 related articles for article (PubMed ID: 9246029)
1. Esophagoprotective potential of cisapride. An additional benefit for gastroesophageal reflux disease.
Goldin GF; Marcinkiewicz M; Zbroch T; Bityutskiy LP; McCallum RW; Sarosiek J
Dig Dis Sci; 1997 Jul; 42(7):1362-9. PubMed ID: 9246029
[TBL] [Abstract][Full Text] [Related]
2. Significant enhancement of esophageal pre-epithelial defense by tegaserod: implications for an esophagoprotective effect.
Majewski M; Jaworski T; Sarosiek I; Sostarich S; Roeser K; Edlavitch SA; Kralstein J; Wallner G; McCallum RW; Sarosiek J
Clin Gastroenterol Hepatol; 2007 Apr; 5(4):430-8. PubMed ID: 17445751
[TBL] [Abstract][Full Text] [Related]
3. A distinct salivary secretory response mediated by the esophago-salivary reflex in patients with Barrett's esophagus: its potential pathogenetic implications.
Yandrapu H; Marcinkiewicz M; Poplawski C; Namiot Z; Zbroch T; Sarosiek J
Adv Med Sci; 2014 Sep; 59(2):281-7. PubMed ID: 25181642
[TBL] [Abstract][Full Text] [Related]
4. Role of saliva in esophageal defense: implications in patients with nonerosive reflux disease.
Yandrapu H; Marcinkiewicz M; Poplawski C; Han K; Zbroch T; Goldin G; Sarosiek I; Namiot Z; Sarosiek J
Am J Med Sci; 2015 May; 349(5):385-91. PubMed ID: 25789686
[TBL] [Abstract][Full Text] [Related]
5. Modulatory effect of esophageal intraluminal mechanical and chemical stressors on salivary prostaglandin E2 in humans.
Namiot Z; Yu ZJ; Piascik R; Hetzel DP; McCallum RW; Sarosiek J
Am J Med Sci; 1997 Feb; 313(2):90-8. PubMed ID: 9030674
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of salivary esophagoprotection: rationale for a physiological approach to gastroesophageal reflux disease.
Sarosiek J; Scheurich CJ; Marcinkiewicz M; McCallum RW
Gastroenterology; 1996 Mar; 110(3):675-81. PubMed ID: 8608875
[TBL] [Abstract][Full Text] [Related]
7. Nizatidine and cisapride enhance salivary secretion in humans.
Adachi K; Ono M; Kawamura A; Yuki M; Fujishiro H; Kinoshita Y
Aliment Pharmacol Ther; 2002 Feb; 16(2):297-301. PubMed ID: 11860413
[TBL] [Abstract][Full Text] [Related]
8. The potential role of the esophageal pre-epithelial barrier components in the maintenance of integrity of the esophageal mucosa in patients with endoscopically negative gastroesophageal reflux disease.
Marcinkiewicz M; Han K; Zbroch T; Poplawski C; Gramley W; Goldin G; Sarosiek J
Am J Gastroenterol; 2000 Jul; 95(7):1652-60. PubMed ID: 10925964
[TBL] [Abstract][Full Text] [Related]
9. Cisapride enhances the effect of partial posterior fundoplication on esophageal peristalsis in GERD patients with poor esophageal contractility.
Wetscher GJ; Glaser K; Wieschemeyer T; Gadenstätter M; Klingler P; Klingler A; Hinder RA
Dig Dis Sci; 1998 Sep; 43(9):1986-90. PubMed ID: 9753263
[TBL] [Abstract][Full Text] [Related]
10. Effects of cisapride on salivary production in normal subjects.
Patel R; Launspach J; Soffer E
Dig Dis Sci; 1996 Mar; 41(3):480-4. PubMed ID: 8617119
[TBL] [Abstract][Full Text] [Related]
11. Impairment of salivary epidermal growth factor secretory response to esophageal mechanical and chemical stimulation in patients with reflux esophagitis.
Rourk RM; Namiot Z; Sarosiek J; Yu Z; McCallum RW
Am J Gastroenterol; 1994 Feb; 89(2):237-44. PubMed ID: 8304310
[TBL] [Abstract][Full Text] [Related]
12. Cisapride decreases gastroesophageal reflux in preterm infants.
Ariagno RL; Kikkert MA; Mirmiran M; Conrad C; Baldwin RB
Pediatrics; 2001 Apr; 107(4):E58. PubMed ID: 11335779
[TBL] [Abstract][Full Text] [Related]
13. Do salivary organic components play a protective role in health and disease of the esophageal mucosa?
Sarosiek J; McCallum RW
Digestion; 1995; 56 Suppl 1():32-7. PubMed ID: 7556968
[TBL] [Abstract][Full Text] [Related]
14. Salivary function in patients with reflux esophagitis: effect of cisapride.
Chen SD; Kao CH; Chang CS; Chen GH
J Nucl Med; 1998 Aug; 39(8):1449-52. PubMed ID: 9708526
[TBL] [Abstract][Full Text] [Related]
15. Esophageal pH assessment of gastroesophageal reflux in 18 patients and the effect of two prokinetic agents: cisapride and metoclopramide.
Rode H; Stunden RJ; Millar AJ; Cywes S
J Pediatr Surg; 1987 Oct; 22(10):931-4. PubMed ID: 3681625
[TBL] [Abstract][Full Text] [Related]
16. Interrelationship between esophageal challenge with mechanical and chemical stimuli and salivary protective mechanisms.
Namiot Z; Rourk RM; Piascik R; Hetzel DP; Sarosiek J; McCallum RW
Am J Gastroenterol; 1994 Apr; 89(4):581-7. PubMed ID: 8147362
[TBL] [Abstract][Full Text] [Related]
17. Prokinetic therapy in gastroesophageal reflux disease.
Champion MC
Can J Gastroenterol; 1997 Sep; 11 Suppl B():55B-65B. PubMed ID: 9347180
[TBL] [Abstract][Full Text] [Related]
18. [A new prokinetic drug cisapride: pharmacological properties and clinical potential].
Sheptulin AA; Muradov NN
Klin Med (Mosk); 1997; 75(7):53-6. PubMed ID: 9411058
[No Abstract] [Full Text] [Related]
19. Salivary bicarbonate as a major factor in the prevention of upper esophageal mucosal injury in gastroesophageal reflux disease.
Skoczylas T; Yandrapu H; Poplawski C; Asadi M; Wallner G; Sarosiek J
Dig Dis Sci; 2014 Oct; 59(10):2411-6. PubMed ID: 24610537
[TBL] [Abstract][Full Text] [Related]
20. Effects of cisapride on parameters of oesophageal motility and on the prolonged intraoesophageal pH test in infants with gastro-oesophageal reflux disease.
Cucchiara S; Staiano A; Boccieri A; De Stefano M; Capozzi C; Manzi G; Camerlingo F; Paone FM
Gut; 1990 Jan; 31(1):21-5. PubMed ID: 2180792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
